Capecitabine
Clinical Response
National Cancer Institute, EgyptSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Clinical Response cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin National Cancer Institute, Egypt | Phase 2 | B |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →